Skip to main content

EFCG joins Critical Medicines Alliance

CEFIC sector group the European Fine Chemicals Group (EFCG), which represents some 350 API and fine chemical sites in Europe, has joined the Critical Medicines Alliance. This is a European Commission initiative that seeks to bring stakeholders together to share challenges and determine the most suitable actions to rebuild resilience in European medicine supply chains

Lonza launches AI-enabled route scouting

Lonza has launched its AI-enabled route scouting service offering for small molecules, which combines AI-enabled computer-aided synthesis planning technology from Elsevier operation Reaxys with its own process R&D expertise and supply chain databases. This aims to streamline synthetic route identification.

Recipharm splits under new owner

Blue Wolf Capital Partners, a US-based private equity firm, has agreed to acquire seven Recipharm sites from EQT Private Equity, subject to regulatory approval in a deal that should close in Q4. These are located at Solna, Strängnäs, Höganäs, Karlskoga and Uppsala in Sweden; Pessac, France; and Parets, Spain.

Diketenes facility commissioned

Jubilant Ingrevia has commissioned a new 2,000 tonnes/year facility for diketene derivatives at Gajraula in India’s Uttar Pradesh state. The company’s supplies these to the pharmaceuticals, agrochemicals and other industries, including the US and the EU. This and early efforts to get customer product approvals, are expected to account for much of the capacity utilisation in the coming months.

EuroAPI suspends Italian site

EuroAPI has suspended all API production at its site in Brindisi, Italy, until further notice. This followed an internal audit in which “quality control deficiencies due to potential local misconduct” were identified. These are being further investigated.

Grace completes CDMO expansion

W.R. Grace has formally opened an expansion of the pharmaceutical CDMO expansion project it began 21 months ago at its site in South Haven, Michigan. The expansion has added 25% more capacity, including a new 15 m3 Hastelloy centrifuge and three 15 m3 multi-purpose chemical reactors.

Almac doubles peptide capacity

Almac Group has announced the completion of two new purpose-built facilities at its headquarters in Craigavon, Northern Ireland. The total investment is about $400 million and is part of a global investment programme announced in June 2022.

One is a 2,600 m2 GMP facility that more than doubles peptide API manufacturing capacity. This “will enhance synthesis, purification and isolation capabilities and meet anticipated demand for clinical development and commercial products”, the company said.

Subscribe to Pharmaceuticals